Accordingly, the combination of tasquinimod with immunotherapy using tumour-targeted superantigens (TTS) resulted in a significant enhancement of anti-tumour effects and an increase in the number of tumour-infiltrating CD8+ T cells in the mouse B16 melanoma model [41]. This evidence concerns the gene CD8A and neoplasm.